379 related articles for article (PubMed ID: 30824612)
21. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
22. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
23. Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).
García-Albéniz X; Alonso V; Escudero P; Méndez M; Gallego J; Rodríguez JR; Salud A; Fernández-Plana J; Manzano H; Zanui M; Falcó E; Feliu J; Gil M; Fernández-Martos C; Bohn U; Alonso C; Calderero V; Rojo F; Cuatrecasas M; Maurel J
Oncologist; 2019 Nov; 24(11):e1115-e1122. PubMed ID: 31235483
[TBL] [Abstract][Full Text] [Related]
24. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
Snyder M; Bottiglieri S; Almhanna K
Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
[TBL] [Abstract][Full Text] [Related]
25. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
26. The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer.
Jia J; Zhang P; Gou M; Yang F; Qian N; Dai G
Dis Markers; 2019; 2019():6812045. PubMed ID: 30805037
[TBL] [Abstract][Full Text] [Related]
27. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
[TBL] [Abstract][Full Text] [Related]
28. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
[TBL] [Abstract][Full Text] [Related]
29. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Normanno N; Esposito Abate R; Lambiase M; Forgione L; Cardone C; Iannaccone A; Sacco A; Rachiglio AM; Martinelli E; Rizzi D; Pisconti S; Biglietto M; Bordonaro R; Troiani T; Latiano TP; Giuliani F; Leo S; Rinaldi A; Maiello E; Ciardiello F;
Ann Oncol; 2018 Jan; 29(1):112-118. PubMed ID: 28950295
[TBL] [Abstract][Full Text] [Related]
30. Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
Dercle L; Lu L; Schwartz LH; Qian M; Tejpar S; Eggleton P; Zhao B; Piessevaux H
J Natl Cancer Inst; 2020 Sep; 112(9):902-912. PubMed ID: 32016387
[TBL] [Abstract][Full Text] [Related]
31. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
[TBL] [Abstract][Full Text] [Related]
32. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
Cuyàs E; Queralt B; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Oncol Rep; 2017 Jul; 38(1):263-270. PubMed ID: 28560458
[TBL] [Abstract][Full Text] [Related]
33. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Laurent-Puig P; Grisoni ML; Heinemann V; Liebaert F; Neureiter D; Jung A; Montestruc F; Gaston-Mathe Y; Thiébaut R; Stintzing S
Clin Cancer Res; 2019 Jan; 25(1):134-141. PubMed ID: 30108104
[TBL] [Abstract][Full Text] [Related]
34. Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for
Maron SB; Alpert L; Kwak HA; Lomnicki S; Chase L; Xu D; O'Day E; Nagy RJ; Lanman RB; Cecchi F; Hembrough T; Schrock A; Hart J; Xiao SY; Setia N; Catenacci DVT
Cancer Discov; 2018 Jun; 8(6):696-713. PubMed ID: 29449271
[TBL] [Abstract][Full Text] [Related]
35. Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.
Price T; Shen L; Ma B; Esser R; Chen W; Gibbs P; Lim R; Cheng AL
Asia Pac J Clin Oncol; 2019 Aug; 15(4):225-230. PubMed ID: 31090260
[TBL] [Abstract][Full Text] [Related]
36. Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.
Torlot L; Jarzab A; Albert J; Pók-Udvari Á; Stahler A; Holch JW; Gerlinger M; Heinemann V; Klauschen F; Kirchner T; Kumbrink J; Küster B; Jung A
J Cancer Res Clin Oncol; 2023 Feb; 149(2):669-682. PubMed ID: 36401637
[TBL] [Abstract][Full Text] [Related]
37. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
38. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
Shi Y; Wan X; Tan C; Li J; Peng L
Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066
[TBL] [Abstract][Full Text] [Related]
39. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
[TBL] [Abstract][Full Text] [Related]
40. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
